President Donald Trump's introduction of a Pfizer executive at the White House Wednesday was met with a roar of boos from the ...

Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors. Beqvez is a one-time therapy ...

"We're also have the head of Pfizer here. One of the great businessmen," Trump said. The raucous boos that followed rattled the president, who giggled, then continued going around ...

Pfizer (PFE) will end global development and commercialization of Beqvez, a gene therapy for hemophilia, Nikkei learned Thursday, after the ...

Pfizer (PFE) discontinues Beqvez hemophilia B therapy developed with Roche (RHHBY) due to low demand, shifting focus to an ...

Pfizer will end global development of its bleeding disorder gene therapy, Beqvez, the Nikkei reported on Thursday.

An intriguing battle is brewing in the market to treat patients with transthyretin amyloid cardiomyopathy (ATTR-CM). | BridgeBio reported that 1,028 unique prescriptions have been written by 516 ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

The Make America Healthy Again commission is taking action on mRNA vaccines as several states consider legislation to ban ...